Anavex Life Sciences Corp AVXL Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Mar 28, 2024 (filed on Apr 01, 2024)

Insider Name:

Missling Christopher U

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-73,380

Price:

--
Mar 28, 2024 (filed on Apr 01, 2024)

Insider Name:

Missling Christopher U

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-73,380

Price:

$5.11
Mar 28, 2024 (filed on Apr 01, 2024)

Insider Name:

Missling Christopher U

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

73,380

Price:

$1.32
Feb 20, 2024 (filed on Feb 23, 2024)

Insider Name:

Donhauser Peter D.O.

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

50,000

Price:

--
Feb 20, 2024 (filed on Feb 23, 2024)

Insider Name:

Velden Claus Vander

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

50,000

Price:

--
Feb 20, 2024 (filed on Feb 23, 2024)

Insider Name:

Thomas Steffen

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

50,000

Price:

--
Feb 20, 2024 (filed on Feb 23, 2024)

Insider Name:

Ma Jiong

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

50,000

Price:

--
Feb 20, 2024 (filed on Feb 23, 2024)

Insider Name:

Skarpelos Athanasios

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

50,000

Price:

--
Jan 02, 2024 (filed on Jan 12, 2024)

Insider Name:

Missling Christopher U

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

-125,000

Price:

--
Jan 02, 2024 (filed on Jan 12, 2024)

Insider Name:

Boenisch Sandra

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

10,000

Price:

--

Filings by filing date

Mar 28, 2024 (filed on Apr 01, 2024)

Insider Name:

Missling Christopher U

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-73,380

Price:

--
Mar 28, 2024 (filed on Apr 01, 2024)

Insider Name:

Missling Christopher U

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-73,380

Price:

$5.11
Mar 28, 2024 (filed on Apr 01, 2024)

Insider Name:

Missling Christopher U

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

73,380

Price:

$1.32
Feb 20, 2024 (filed on Feb 23, 2024)

Insider Name:

Donhauser Peter D.O.

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

50,000

Price:

--
Feb 20, 2024 (filed on Feb 23, 2024)

Insider Name:

Velden Claus Vander

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

50,000

Price:

--
Feb 20, 2024 (filed on Feb 23, 2024)

Insider Name:

Thomas Steffen

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

50,000

Price:

--
Feb 20, 2024 (filed on Feb 23, 2024)

Insider Name:

Ma Jiong

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

50,000

Price:

--
Feb 20, 2024 (filed on Feb 23, 2024)

Insider Name:

Skarpelos Athanasios

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

50,000

Price:

--
Jan 02, 2024 (filed on Jan 12, 2024)

Insider Name:

Missling Christopher U

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

-125,000

Price:

--
Jan 02, 2024 (filed on Jan 12, 2024)

Insider Name:

Boenisch Sandra

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

10,000

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	630 5Th Avenue, 20Th Floor NEW YORK NY 10111
Tel:	N/A
Website:	https://www.anavex.com
IR:	See website

Key People

Christopher U. Missling Chairman of the Board, President, Chief Executive Officer, Company Secretary	Sandra Boenisch Principal Financial Officer, Treasurer

Business Overview

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company's product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.

Financial Overview

For the three months ended 31 December 2023, Anavex Life Sciences Corp revenues was not reported. Net loss decreased 34% to $8.6M. Lower net loss reflects Research and development - Balancing decrease of 46% to $4.6M (expense), Stock-based Compensation in R&D decrease of 62% to $1.4M (expense), Stock-based Compensation in SGA decrease of 47% to $926K (expense).

Employees:	40 as of Sep 30, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	$168.26M as of Dec 31, 2023
Annual revenue (TTM):	$0.00M as of Dec 31, 2023
EBITDA (TTM):	-$51.67M as of Dec 31, 2023
Net annual income (TTM):	-$43.16M as of Dec 31, 2023
Free cash flow (TTM):	-$29.31M as of Dec 31, 2023
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	82,112,511 as of Feb 7, 2024
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization